Yes, you can switch from enoxaparin to apixaban (Eliquis) for pulmonary embolism treatment.
For patients with acute PE receiving therapeutic enoxaparin, direct oral anticoagulants (DOACs) like apixaban are now the preferred anticoagulant over traditional enoxaparin/warfarin therapy. 1, 2
Switching Protocol
When transitioning from enoxaparin to apixaban:
- Stop enoxaparin and start apixaban at the next scheduled enoxaparin dose 3
- Apixaban dosing for PE: 10 mg orally twice daily for 7 days, then 5 mg twice daily 4, 1, 3
- No overlap period is required—apixaban can be started immediately when the next enoxaparin dose would have been due
Why This Switch Makes Sense
The 2021 CHEST guidelines explicitly recommend DOACs (including apixaban) over vitamin K antagonists for VTE treatment, with a strong recommendation based on moderate-certainty evidence 2. Key advantages include:
- Equal or superior efficacy: Apixaban is non-inferior to enoxaparin/warfarin for preventing recurrent VTE 1, 5
- Significantly less bleeding: Major bleeding rates are substantially lower with apixaban (0.6% vs 1.8% with warfarin) 1
- No parenteral therapy needed: Eliminates subcutaneous injections
- No laboratory monitoring required: Unlike warfarin, no INR checks needed 3
- Reduced hospitalizations: Apixaban significantly reduces all-cause hospitalizations compared to enoxaparin/warfarin (5.72% vs 7.07%, p=0.045) 5
Important Caveats
Do NOT switch if the patient has:
- Cancer-associated thrombosis: LMWH (enoxaparin) remains preferred over DOACs for the first 3 months in cancer patients 1, 6
- Severe renal impairment: Apixaban requires dose adjustment if CrCl <25 mL/min 3
- Triple-positive antiphospholipid syndrome: DOACs are associated with increased thrombotic events in this population; warfarin is preferred 3
- Hemodynamic instability: Apixaban is not recommended as initial therapy for hemodynamically unstable PE 3
Duration of Therapy
Continue apixaban for at least 3 months for acute PE 4, 1. After 3 months, reassess for extended therapy based on:
- Whether the PE was provoked or unprovoked
- Bleeding risk
- Patient preference
For extended therapy beyond 6 months, either full-dose (5 mg twice daily) or reduced-dose (2.5 mg twice daily) apixaban can be considered 4, 1.
The switch from enoxaparin to apixaban is not only appropriate but represents current best practice for most patients with acute PE without the contraindications listed above.